Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004699966 | SCV005205258 | likely pathogenic | Xeroderma pigmentosum | 2024-06-06 | criteria provided, single submitter | clinical testing | Variant summary: ERCC2 c.1623C>G (p.Ser541Arg) results in a non-conservative amino acid change located in the ATP-dependent helicase, C-terminal (IPR006555) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251456 control chromosomes. To our knowledge, no occurrence of c.1623C>G in individuals affected with Xeroderma Pigmentosum and no experimental evidence directly assessing its impact on protein function have been reported. However, a different variant resulting in the same amino acid consequence has been classified as pathogenic by our lab (c.1621A>C, p.Ser541Arg), supporting the pathogenicity of this variant. No submitters have cited clinical-significance assessments for this variant to ClinVar. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Fulgent Genetics, |
RCV005017218 | SCV005648396 | likely pathogenic | Cerebrooculofacioskeletal syndrome 2; Xeroderma pigmentosum, group D; Trichothiodystrophy 1, photosensitive | 2024-06-07 | criteria provided, single submitter | clinical testing |